Fluorouracil and Dihydropyrimidine Dehydrogenase Genotyping Reply

被引：4
|
作者：
Deenen, Maarten J. [1 ,2 ]
Cats, Annemieke [1 ]
Severens, Johan L. [3 ]
Beijnen, Jos H. [1 ,4 ]
Schellens, Jan H. M. [1 ,4 ]
机构：
[1] Netherlands Canc Inst, Amsterdam, Netherlands
[2] Catharina Hosp, Eindhoven, Netherlands
[3] Erasmus Univ, Med Ctr, Rotterdam, Netherlands
[4] Univ Utrecht, Utrecht, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 20期
关键词：
5-FLUOROURACIL TOXICITY; CLINICAL-RELEVANCE; DPYD VARIANTS; METAANALYSIS;
D O I：
10.1200/JCO.2016.67.4374
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：2434 / U206
页数：3
相关论文
共 50 条
  • [41] Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD)
    Ambrodji, Alisa
    Sadlon, Angelique
    Amstutz, Ursula
    Hoch, Dennis
    Berger, Martin D.
    Bastian, Sara
    Offer, Steven M.
    Largiader, Carlo R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [42] Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series
    Nguyen, D. Grace
    Morris, Sarah A.
    Chen, Annabel
    Moore, Donald C.
    Hanson, Sarah L.
    Larck, Chris
    Musselwhite, Laura W.
    Turner, John D.
    Salem, Mohamed E.
    Kwange, Simeon O.
    Hamilton, Alicia
    Steuerwald, Nury
    Patel, Jai N.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22 (04):
  • [43] SEVERE 5-FLUOROURACIL TOXICITY IN A PATIENT WITH DECREASED DIHYDROPYRIMIDINE DEHYDROGENASE-ACTIVITY
    LYSS, AP
    LILENBAUM, RC
    HARRIS, BE
    DIASIO, RB
    CANCER INVESTIGATION, 1993, 11 (02) : 239 - 240
  • [44] Dihydropyrimidine dehydrogenase and thymidylate synthase in relation to 5-fluorouracil sensitivity of breast cancer
    Inomoto, T
    Kitai, T
    Ukikusa, M
    Ino, K
    Higashiyama, H
    Arimoto, A
    Nakajima, Y
    Hanafusa, T
    Awane, H
    Kobayashi, H
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S200 - S200
  • [45] Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance
    Diasio, RB
    Johnson, MR
    CLINICAL CANCER RESEARCH, 1999, 5 (10) : 2672 - 2673
  • [46] A fast and reliable method for genotyping of clinically relevant genetic variants in dihydropyrimidine dehydrogenase (DPYD)
    Meyer, M. J.
    Arnhardt, I.
    Morof, F.
    Tzvetkov, M. V.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2022, 395 (SUPPL 1) : S19 - S19
  • [47] Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment
    Amstutz, Ursula
    Farese, Simone
    Aebi, Stefan
    Largiader, Carlo R.
    PHARMACOGENOMICS, 2009, 10 (06) : 931 - 944
  • [48] Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency
    Shehata, N
    Pater, A
    Tang, SC
    CANCER INVESTIGATION, 1999, 17 (03) : 201 - 205
  • [49] Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy
    Jiang, WQ
    Lu, ZH
    He, YJ
    Diasio, RB
    CLINICAL CANCER RESEARCH, 1997, 3 (03) : 395 - 399
  • [50] Lethal 5-fluorouracil toxicity associated with a novel mutation in the dihydropyrimidine dehydrogenase gene
    van Kuilenburg, ABP
    Baars, JW
    Meinsma, R
    van Gennip, AH
    ANNALS OF ONCOLOGY, 2003, 14 (02) : 341 - 342
12345